Article Figures & Tables
Figures
Figure 1: Selection of randomized placebo-controlled trials for systematic review of effectiveness of paroxetine in the treatment of major depression in adults.
Figure 2: Random effects meta-analysis of the effect of paroxetine versus placebo on the proportion of patients who discontinued treatment for any reason. n = number of patients leaving the study for any reason, N = total number of patients, RR = relative risk, CI = confidence interval. Study designations are defined in online Appendix 2 (www.cmaj.ca/cgi/content/full/178/3/296/DC2).
Figure 3: Random effects meta-analysis of the effect of paroxetine versus placebo on the proportion of patients who showed less than 50% improvement in measures of depression. n = number of patients who did not experience an improvement of at least 50% on depression measure, N = total number of patients, RR = relative risk, CI = confidence interval. Study designations are defined in online Appendix 2 (www.cmaj.ca/cgi/content/full/178/3/296/DC2).
Figure 4: Random effects meta-analysis of the effect of paroxetine versus placebo on standardized depression outcomes. SD = standard deviation, SMD = standardized mean difference, CI = confidence interval. Study designations are defined in online Appendix 2 (www.cmaj.ca/cgi/content/full/178/3/296/DC2).
Figure 5: Random effects meta-analysis of the effect of paroxetine versus placebo on the proportion of patients who reported any adverse effects. n = number of patients who reported any adverse effect, N = total number of patients, RR = relative risk, CI = confidence interval. Study designations are defined in online Appendix 2 (www.cmaj.ca/cgi/content/full/178/3/296/DC2).
Figure 6: Random effects meta-analysis of the effect of paroxetine versus placebo on the proportion of patients who reported suicidal tendencies (as indicated by the coding system of the US Food and Drug Administration19). n = number of patients who reported suicidal tendencies, N = total number of patients, RR = relative risk, CI = confidence interval. Study designations are defined in online Appendix 2 (www.cmaj.ca/cgi/content/full/178/3/296/DC2).
In this issue
Article tools
Jump to section
Related Articles
Cited By...
- Suicide risk with selective serotonin reuptake inhibitors and other new-generation antidepressants in adults: a systematic review and meta-analysis of observational studies
- Suicide risk with selective serotonin reuptake inhibitors and new-generation serotonergic-noradrenergic antidepressants in adults: a systematic review and meta-analysis of observational studies
- Efficacy of selective serotonin reuptake inhibitors and adverse events: meta-regression and mediation analysis of placebo-controlled trials
- Accounting for baseline differences in meta-analysis
- The Chemical Imbalance Hypothesis: An Evaluation of the Evidence
- Beneficial and harmful consequences of prepartum and postpartum antidepressant exposure
- Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials
- Publication bias: What are the challenges and can they be overcome?
- Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses
- EMA must improve the quality of its clinical trial reports
- Making the best use of available evidence: the case of new generation antidepressants: A response to: Are all antidepressants equal?
- Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies
- Selective serotonin reuptake inhibitors for unipolar depression: a systematic review of classic long-term randomized controlled trials
- Effectiveness of selective serotonin reuptake inhibitors
- Effectiveness of selective serotonin reuptake inhibitors
More in this TOC Section
Similar Articles
